DANIELLE GLICK: Open Payments
NPI 1104230531 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,516 in 124 payments from 22 companies in 2025. Trend: 2023 $1,710 · 2024 $2,562 · 2025 $2,516
Food & beverage: $2,516
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $577 |
| Janssen Biotech, Inc. | 12 | $245 |
| Ardelyx, Inc. | 16 | $223 |
| Madrigal Pharmaceuticals | 11 | $203 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $159 |
| GENZYME CORPORATION | 4 | $142 |
| Aimmune Therapeutics, Inc. | 5 | $132 |
| Regeneron Pharmaceuticals, Inc. | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $120 |
| Phathom Pharmaceuticals, Inc. | 7 | $98 |
Products named: DUPIXENT, RINVOQ, TREMFYA, IBSRELA, REZDIFFRA, XIFAXAN, CREON, ZENPEP.
Industry payments across IN — which companies pay providers there.
